rare frequency of gene variation and survival analysis in thymic epithelial tumors

Objective: Thymic epithelial tumor (TET) is a rare mediastinal neoplasm and little is known about its genetic variability and prognostic factors. This study investigated the genetic variability and prognostic factors of TET. Patients and methods: We sequenced 22 cancer-related hotspot genes in TET tissues and matched normal tissues using Ampliseq Ion Torrent next-generation technology. Overall survival was evaluated using Kaplan–Meier methods and compared with log-rank tests

[1]  Jian-Hua Fu,et al.  Management of thymic tumors-consensus based on the Chinese Alliance for Research in Thymomas Multi-institutional retrospective studies. , 2016, Journal of thoracic disease.

[2]  A. Marx,et al.  Clinicopathological analysis of 241 thymic epithelial tumors-experience in the Shanghai Chest Hospital from 1997-2004. , 2016, Journal of thoracic disease.

[3]  H. Asamura,et al.  Long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a Japanese Nationwide Database Study. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[4]  Wenke Liu,et al.  Thymic carcinoma patients with myasthenia gravis exhibit better prognoses , 2016, International Journal of Clinical Oncology.

[5]  Jian-Hua Fu,et al.  Long-Term Survival After Surgical Treatment of Thymic Carcinoma: A Retrospective Analysis from the Chinese Alliance for Research of Thymoma Database , 2016, Annals of Surgical Oncology.

[6]  P. Meltzer,et al.  Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. , 2015, The Lancet. Oncology.

[7]  M. Hellmich,et al.  PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies , 2014, Oncotarget.

[8]  H. Sasaki,et al.  Genetic profiling of thymic carcinoma using targeted next-generation sequencing. , 2014, Lung cancer.

[9]  Jaime Rodriguez-Canales,et al.  A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors , 2014, Nature Genetics.

[10]  G. Giaccone,et al.  Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. , 2014, The Lancet. Oncology.

[11]  P. Stephens,et al.  Thymoma Patients Treated in a Phase I Clinic at MD Anderson Cancer Center: Responses to mTOR Inhibitors and Molecular Analyses , 2013, Oncotarget.

[12]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..

[13]  Razelle Kurzrock,et al.  PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[15]  H. Sasaki,et al.  Evaluation of Kras gene mutation and copy number in thymic carcinomas and thymomas. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  A. Marx,et al.  Sunitinib in metastatic thymic carcinomas: Laboratory findings and initial clinical experience , 2010, British Journal of Cancer.

[17]  N. Girard,et al.  Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas , 2009, Clinical Cancer Research.

[18]  G. Rossi,et al.  Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  H. Ohmatsu,et al.  Mutational status of EGFR and KIT in thymoma and thymic carcinoma. , 2008, Lung cancer.

[20]  H. Sasaki,et al.  Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. , 2006, Japanese journal of clinical oncology.

[21]  W. Pao,et al.  Phase II study of gefitinib treatment in advanced thymic malignancies , 2005 .

[22]  A. Marx,et al.  Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. , 2004, The New England journal of medicine.

[23]  C. Pan,et al.  Expression of apoptosis‐related markers and HER‐2/neu in thymic epithelial tumours , 2003, Histopathology.

[24]  R. Pfeiffer,et al.  Malignant thymoma in the United States: Demographic patterns in incidence and associations with subsequent malignancies , 2003, International journal of cancer.

[25]  J. Welsh,et al.  Thymoma and multiple malignancies: a case of five synchronous neoplasms and literature review. , 2003, Clinical medicine & research.

[26]  A. Rosenwald,et al.  Recurrent genetic aberrations in thymoma and thymic carcinoma. , 2000, The American journal of pathology.

[27]  H. Asamura,et al.  A review of 79 thymomas: Modification of staging system and reappraisal of conventional division into invasive and non‐invasive thymoma , 1994, Pathology international.

[28]  Y. Tseng,et al.  Thymic neuroendocrine carcinoma and thymoma are both associated with increased risk of extrathymic malignancy: a 20-year review of a single institution. , 2011, The Annals of thoracic surgery.